ArticleTherapeutic advances in musculoskeletal disease2020
Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet's syndrome: case series and literature review.
Article in Therapeutic advances in musculoskeletal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Severe neuro-behçet's disease refractory: Radiologic improvement with tocilizumab.Radiology case reports · 2026Article
- Clinical Use of Interleukin-6 Blockade in Neuroimmunological Disorders.Noro psikiyatri arsivi · 2026Review
- New and future perspectives in Behçet's syndrome.Archives of rheumatology · 2024Review
- SAPHO syndrome: current clinical, diagnostic and treatment approaches.Rheumatology international · 2024Review
- NeuroBehcet's-related intracranial hypertension without cerebral venous thrombosis: case report and review of literature.BMC neurology · 2024Review
- The roles of immune cells in Behçet's disease.Advances in rheumatology (London, England) · 2023Review
- Refractory systemic lupus erythematosus with chylous effusion successfully treated with sirolimus: a case report and literature review.Rheumatology international · 2023Review
- Molecular and therapeutic insights of rapamycin: a multi-faceted drug from Streptomyces hygroscopicus.Molecular biology reports · 2023Review
- Treatment Options in Pediatric Behçet's Disease.Paediatric drugs · 2023Review
- Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet's disease.Turkish journal of medical sciences · 2022Article
- Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.Therapeutic advances in gastroenterology · 2022Article
- A Contemporary Review of Behcet's Syndrome.Clinical reviews in allergy & immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the efficacy and safety of tocilizumab (TCZ) in severe and refractory parenchymal neuro-Behçet's syndrome (p-NBS).
methodsWe retrospectively analyzed five patients with p-NBS treated with TCZ in our center between 2013 and 2020, and six cases from literature research with the index terms "neuro-Behçet's syndrome" and "tocilizumab" on PubMed NCBI.
resultsA total of 11 patients with p-NBS were enrolled (5 males, 6 females), with a mean age of 34.5 ± 8.0 years at the onset. All the patients had parenchymal neurological lesions, six patients (54.5%) suffered from multiple lesions, and nine patients (81.8%) were disabled. Before TCZ administration, all the patients had failed conventional therapy, eight patients (72.7%) received two or more immunosuppressants, and five patients showed insufficient response or intolerance to other biologics. TCZ was administrated at 8 mg/kg every 4 weeks, with background glucocorticoids (GCs) and immunosuppressants. After a median follow-up of 13 (interquartile range, 3.5-23.5) months, all the patients achieved both clinical and radiological improvements, and the Behçet's Disease Current Activity Form score improved significantly (3
conclusionsTCZ is well tolerated and effective in severe and refractory p-NBS, with a favorable GC- and immunosuppressant-sparing effect. Cerebrospinal fluid interleukin-6 might be used to monitor the effects of TCZ in p-NBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.